{
    "organizations": [],
    "uuid": "29660075a60a8b5efb7e3c10de1e8a86b0254266",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-celldex-therapeutics-reports-q4-lo/brief-celldex-therapeutics-reports-q4-loss-per-share-0-03-idUSL5N1QP74U",
    "ord_in_thread": 0,
    "title": "BRIEF-Celldex Therapeutics Reports Q4 Loss Per Share $0.03",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7 (Reuters) - Celldex Therapeutics Inc:\n* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 RESULTS\n* Q4 LOSS PER SHARE $0.03 * CELLDEX THERAPEUTICS - ANTICIPATE TOPLINE PRIMARY ENDPOINT DATA FROM METRIC STUDY OF GLEMBATUMUMAB VEDOTIN WILL BE AVAILABLE IN Q2 OF 2018\n* Q4 REVENUE $3.5 MILLION VERSUS $1.9 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-08T05:57:00.000+02:00",
    "crawled": "2018-03-08T17:25:18.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "celldex",
        "therapeutic",
        "inc",
        "celldex",
        "provides",
        "corporate",
        "update",
        "report",
        "full",
        "year",
        "result",
        "q4",
        "loss",
        "per",
        "share",
        "celldex",
        "therapeutic",
        "anticipate",
        "topline",
        "primary",
        "endpoint",
        "data",
        "metric",
        "study",
        "glembatumumab",
        "vedotin",
        "available",
        "q2",
        "q4",
        "revenue",
        "million",
        "versus",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}